Replies to post #18153 on MannKind Corp. (MNKD)

[leslunier]

I agree. Management should have had their plan ready to be announced when they retained rights to afrezza. God knows they had months to plan it. Frankly I don't think this ceo is any smarter than the last one. I see nightly ads on tv for tuojeo from sanofi but never saw one for afrezza. Really where was management this past year?

[exwannabe]

Why do you assume there is a solution to the problem?

SNY had a large and expensive sales force targeting the docs who matter. Even making a half hearted effort it was more resources than MNKD can afford to spin up.

MNKD now has to cover the entire bill (before they "owed" half, but did not have to pay any because of the SNY loan). And want to spin up a sales force?

The only "Hail Mary" they had was a new partner, which seemed a stretch as why would somebody else pay for something that SNY gave up on? And now it seems like that hope is fading as they plan to self market the drug.

This story (MNKD that is, not Alfrezza) will be over when the Q3 financials post (Q2 will be murky due to the SNY cancellation terms). At that point there will be no avoiding financial reality.

This stock was trading well under $1. A nice pump/dump job got it up over $2, and now we see the back end.